Advanced search
Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 43, 2024 - Issue 1
Submit an article Journal homepage
203
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Ipilimumab-related orbitopathy: a case report

Abigail P. Jebaraja Moran Eye Center, University of Utah John A., Salt Lake City, Utah, USACorrespondence[email protected]
View further author information
,
Tyler J. Etheridgea Moran Eye Center, University of Utah John A., Salt Lake City, Utah, USAView further author information
,
Blair A. Winegarb Department of Radiology & Imaging Sciences, University of Utah, Salt Lake City, Utah, USAView further author information
&
Douglas P. Marxa Moran Eye Center, University of Utah John A., Salt Lake City, Utah, USAView further author information
Pages 100-104 | Received 19 Dec 2021, Accepted 29 Apr 2022, Published online: 17 May 2022

References

  • Hassanzadeh B, DeSanto J, Kattah JC. Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management. Neuroophthalmology. 2018;42(3):176–181. doi:10.1080/01658107.2017.1368090.
  • Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM. Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140–146. doi:10.3109/09273948.2014.1001858.
  • Sheldon CA, Kharlip J, Tamhankar MA. Inflammatory orbitopathy associated with ipilimumab. Ophthalmic Plast Reconstr Surg. 2017;33(3S Suppl 1):S155–S158. doi:10.1097/IOP.0000000000000509.
  • Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–1078. doi:10.1097/IAE.0000000000002181.
  • Cunningham ET, London NJ, Moorthy R, Garg SJ, Zierhut M. Inflammation, and the EyeDrugs, inflammation, and the eye. Ocul Immunol Inflamm. 2016;24(2):125–127. doi:10.3109/09273948.2016.1160683.
  • Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. Sep 01 2005;23(25):6043–6053. doi:10.1200/JCO.2005.06.205.
  • Borodic G, Hinkle DM, Cia Y. Drug-Induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg. 2011;27(4):e87–8. doi:10.1097/IOP.0b013e3181ef72a1.
  • Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164(2):303–307. doi:10.1530/EJE-10-0833.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.